Improving the efficacy of antibody-based cancer therapies

@article{Carter2001ImprovingTE,
  title={Improving the efficacy of antibody-based cancer therapies},
  author={P. Carter},
  journal={Nature Reviews Cancer},
  year={2001},
  volume={1},
  pages={118-129}
}
  • P. Carter
  • Published 2001
  • Medicine
  • Nature Reviews Cancer
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies. 
Monoclonal Antibodies as Cancer Therapeutics
TLDR
The most significant breakthroughs in the development of monoclonal antibodies as oncology therapeutics have been the selective targetting of these agents on tumor cells and drug discovery and development. Expand
Development trends for monoclonal antibody cancer therapeutics
TLDR
Trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980 are overviewed with the aim of informing future research and development for this class of therapeutics. Expand
Monoclonal antibodies as therapeutics in oncology.
The specificity of antibodies has been harnessed to target cancer cells and the first therapeutic antibodies for use in oncology are now finding application in the clinic. Studies are currently underExpand
FLT3 Antibody-Based Therapeutics for Leukemia Therapy
TLDR
Some basic aspects of antibody-based cancer therapeutics, including their mechanisms of action, are discussed, with a focus on recent progress in the generation and development of anti-FLT3 antibodies as well as their therapeutic potentials in the treatment of human hematologic malignancies. Expand
Potent antibody therapeutics by design
  • P. Carter
  • Biology, Medicine
  • Nature Reviews Immunology
  • 2006
TLDR
The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential. Expand
Comparing antibody and small-molecule therapies for cancer
The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds haveExpand
Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy
TLDR
This review provides a brief historical sketch of the development of monoclonal antibodies for cancer treatment and summarizes the most significant clinical data for the best-established reagents to date. Expand
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
TLDR
This review summarizes the current knowledge and developments in the field of antibody drug conjugates. Expand
Antibody fusions with immunomodulatory proteins for cancer therapy.
TLDR
Factors influencing the selection and modification of cytokines and antibody formats for targeted delivery by antibody fusion proteins are being discussed, indicating current developments and translational advances in the field. Expand
Recombinant antibodies and tumor targeting
TLDR
Antibody engineering has added significant new technologies to modify size, affini size, and properties of antibody derived constructs as putative tools for treatment of malignant diseases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 151 REFERENCES
Bispecific antibodies in cancer therapy.
TLDR
Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients and showed beneficial effects in some patients. Expand
Recent developments in the radioimmunotherapy of cancer.
TLDR
Advances in molecular biology, immunology and radiochemistry will allow the continued development of strategies to overcome the remaining obstacles to effective therapy with radioimmunoconjugates. Expand
Immunotherapeutic perspective for bispecific antibodies.
TLDR
How results of recent studies underline the importance of both the 'anti-trigger' and ' anti-target' modalities of BsAb for therapeutic efficacy are discussed. Expand
Clinical trials of antibody therapy.
TLDR
The situation has changed dramatically in the past five years, with numerous mAbs now showing clinical potential, and a further seven approved for human treatment, and all indications are that this upward trend will continue. Expand
Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
TLDR
It is concluded that ADEPT holds the potential of an effective and relatively non-toxic treatment of cancer and it is expected that the research which is in progress will makeADEPT an important element of the anticancer armament. Expand
Bispecific antibodies in cancer therapy, from the laboratory to the clinic.
Bispecific monoclonal antibodies (BiMAb) have been shown to be able to contribute to an immunological approach in cancer therapy. In this review, essential aspects regarding the production of BiMAbExpand
Human antibodies by design
TLDR
Mabs that are entirely human are now being produced from phage display and transgenic mice, and together with recent advances in these technologies, may finally realize the full potential of antibodies. Expand
The development of monoclonal antibodies for the therapy of cancer.
TLDR
This review discusses Mab-based strategies for the treatment of cancer and compares native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. Expand
Antibody-Based targeting of angiogenesis.
  • C. Halin, D. Neri
  • Medicine
  • Critical reviews in therapeutic drug carrier systems
  • 2001
TLDR
Recent progress in the generation of monoclonal antibodies, which recognize and target new blood vessels in vivo, while sparing mature vessels and healthy tissues are reviewed. Expand
Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
TLDR
The design, synthesis, physico-chemical and biological properties, kinetics and clinical trials of the prodrugs and the enzymes carboxypeptidase G2 and nitroreductase are reviewed for ADEPT and GDEPT. Expand
...
1
2
3
4
5
...